Randomized dose-controlled study of topiramate as first-line therapy in epilepsy

Acta Neurologica Scandinavica

Volumn 112, Issue 4, 2005, Pages 214-222

  Arroyo, S ^a,h   Dodson, W E ^b   Privitera, M D ^c   Glauser, T A ^d   Naritoku, D K ^e   Dlugos, D J ^f   Wang, S ^f   Schwabe, S K ^g,i   Twyman, Roy E ^g  

^a HOSPITAL CLÍNIC   (Spain)

^b ST LOUIS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^h EISAI INC   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anticonvulsant; Epilepsy; Topiramate

Indexed keywords

TOPIRAMATE;

ADOLESCENT; ADULT; AGED; APPETITE DISORDER; ARTICLE; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 25144453313     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00485.x     Document Type: Article

References (31)

1. FRENCH JA, SCHACHTER S. A workshop on antiepileptic drug monotherapy indications. Epilepsia 2002;43(Suppl. 10):3-27.
2. Report of the ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39:799-803.
3. CHADWICK D, PRIVITERA M. Placebo-controlled studies in neurology: where do they stop? Neurology 1999;52:682-5.
4. FAUGHT E, WILDER BJ, RAMSAY RE et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
5. PRIVITERA M, FINCHAM R, PENRY J et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-83.
6. SHARIEF M, VITERI C, BEN-MENACHEM E et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
7. TASSINARI CA, MICHELUCCI R, CHAUVEL P et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
8. BEN-MENACHEM E, HENRIKSEN O, DAM M et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
9. ELTERMAN RD, GLAUSER TA, WYLLIE E, REIFE R, WU S-C, PLEDGER G, THE TOPIRAMATE YP STUDY GROUP. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999;52:1338-44.
10. SACHDEO RC, GLAUSER TA, RITTER F, REIFE R, LIM P, PLEDGER G, THE TOPIRAMATE YL STUDY GROUP. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52:1882-7.
11. BITON V, MONTOURIS GD, RITTER F et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-7.
12. GUBERMAN A, NETO W, GASSMANN-MAYER C, THE EPAJ-119 STUDY GROUP. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002;106:183-9.
13. COMMISSION ON CLASSIFICATION AND TERMINOLOGY OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
14. GILLIAM FG, VELOSO F, BOMHOF MAM et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003;60:196-202.
15. LACHIN JM, FOULKES MA. Evaluation of sample size and power for analyses of survival with allowance for non-uniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-16.
16. MACDONALD BK, JOHNSON AL, GOODRIDGE DM, COCKERELL OC, SANDER JWAS, SHORVON SD. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000;48:833-41.
17. STEINER TJ, DELLAPORTAS CI, FINDLEY LJ et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
18. BRODIE MJ, RICHENS A, YUEN AWC, FOR UK LAMOTRIGINE/CARBAMAZEPINE MONOTHERAPY TRIAL GROUP. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
19. PRIVITERA MD, BRODIE MJ, MATTSON RH, CHADWICK DW, NETO W, WANG S, FOR THE EPMN 105 STUDY GROUP. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75.
20. CHADWICK D, FOR THE VIGABATRIN EUROPEAN MONOTHERAPY STUDY GROUP. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a mulicentre randomised double-blind study. Lancet 1999;354:13-9.
21. MATTSON RH, CRAMER JA, COLLINS JF AND THE DEPARTMENT OF VETERANS AAIRS EPILEPSY COOPERATIVE STUDIES No. 118 AND No. 264 GROUP. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology 1996;47:68-76.
22. MATTSON RH, CRAMER JA, COLLINS JF et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
23. MATTSON RH, CRAMER JA, COLLINS JF AND THE VA EPILEPSY COOPERATIVE STUDY GROUP. Success with alternate antiepileptic drug selection. Epilepsia 1986;27:645.
24. KWAN P, BRODIE MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
25. BERG AT, SHINNAR S, LEVY SR, TESTA FM, SMITH-RAPAPORT S, BECKERMAN B. Early development of intractable epilepsy in children. Neurology 2001;56:1445-52.
26. SILLANPÄÄ M, JALAVA M, KALEVA O, SHINNAR S. Long-term prognosis of seizures with onset in childhood. N Engl J Med 1998;338:1715-22.
27. DAM M, EKBERG R, LØYNING Y, WALTIMO O, JAKOBSEN K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-6.
28. CHRISTE W, KRÄMER G, VIGONIUS U et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60.
29. BILL PA, VIGONIUS U, POHLMANN H et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997;27:195-204.
30. GUERREIRO MM, VIGONIUS U, POHLMANN H et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27:205-13.
31. KWAN P, BRODIE MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42:1255-60.